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Abstract
In this report we utilized zebrafish (Danio rerio) embryos in a phenotypical high-content screen 
(HCS) to identify novel leads in a cancer drug discovery program. We initially validated our HCS 
model using the flavin adenosine dinucleotide (FAD) containing endoplasmic reticulum (ER) 
enzyme, endoplasmic reticulum oxidoreductase (ERO1) inhibitor EN460. EN460 showed a dose 
response effect on the embryos with a dose of 10 μM being significantly lethal during early 
embryonic development. The HCS campaign which employed a small library identified a 
promising lead compound, a naphthyl-benzoic acid derivative coined compound 1 which had 
significant dosage and temporally dependent effects on notochord and muscle development in 
zebrafish embryos. Screening a 369 kinase member panel we show that compound 1 is a PIM3 
kinase inhibitor (IC50 = 4.078 μM) and surprisingly a DAPK1 kinase agonist/activator (EC50 = 
39.525 μM). To our knowledge this is the first example of a small molecule activating DAPK1 
kinase. We provide a putative model for increased phosphate transfer in the ATP binding domain 
when compound 1 is virtually docked with DAPK1. Our data indicate that observable 
phenotypical changes can be used in future zebrafish screens to identify compounds acting via 
similar molecular signaling pathways.
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Cancer is a complex disease group with more than 100 specific subtypes. There are more 
than a million new cancer patients estimated in 2016.1 To identify novel molecular targets 
and develop oncology therapeutics remains an important goal to adequately and successfully 
treat cancer patients.2 One approach to identify novel drugable targets is the use of high 
content phenotypic screens using whole organisms.3 The use of whole organism screens 
naturally selects for compounds which have a profile that is drug-like in nature, with 
intrinsic pharmacokinetic and toxicological effects part of a hit compound. Several of these 
type of phenotypical screens have been described, including the fruit fly (Drosophila 
melanogaster)4 as well as the zebrafish (Danio rerio).3, 5 Several studies have shown that 
these organisms can be used for high throughput screening (HTS) and for identifying novel 
compounds to be used in drug development campaigns. In this study, we screened an in-
house compound library of 80 structurally diverse compounds using a zebrafish embryo high 
content screen (HCS) in a 96-well plate format, to identify novel compounds which may 
have utility in cancer drug discovery programs.
Compounds were initially screened at 100 μM and embryos evaluated daily for observable 
developmental changes using a dissecting microscope. Our library was made up of several 
compounds from previous studies,6, 7 and the compounds were originally obtained from 
Chembridge (www.hit2lead.com). In this study, we screened 80 compounds which were 
each representative of a chemotype for which we have additional compound to explore 
structure-activity relationship studies, latter kept in separate plates. From this screen we 
visually evaluated each of 96 wells per plate containing a single embryo for changes in 
phenotype. Our initial criterion were embryotic death (observed as loss of structure), gross 
deformities, or delayed hatching from egg sack.
A culmination of the results of our HCS validation and testing are shown in figures 1 and 2 
respectively. Zebrafish eggs were collected, staged, and placed in 12-well plates with E3 
embryo media within the first 6 hours post fertilization (hpf). Tests were done between 6–
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30hpf and also after 30hpf. Each well contained 1 mL of E3 media plus 1% DMSO with or 
without the compound at the initially screened and additional concentrations. No more than 
30 embryos were tested per well. As a control compound, we used EN460 to establish the Z-
score for this HCS assay. EN460 is an inhibitor of the Flavin adenosine dinucleotide (FAD) 
containing endoplasmic reticulum (ER) enzyme endoplasmic reticulum oxidoreductase 
(ERO1). ERO1L is an endoplasmic reticulum resident oxidoreductase which utilizes oxygen 
and FAD to form denovo disulfide bridges. ERO1L shuttles disulfide bridges to protein 
disulfide isomerase (PDI) which in turn oxides target proteins and contributes to protein 
folding.8 EN460 is reported to inhibit the ERO1L enzyme with an IC50 of 1.9 μM.8 
Bioinformatics data mining indicated that the ERO1 enzyme is present in zebrafish, however 
the gene encoding this enzyme was duplicated during teleost evolution (ero1a, NM_200350 
and ero1b, NM_001076638). We wanted to validate this HCS with EN460 so that we could 
identify novel compounds which interact with proteins a priori of knowing the specific 
target. Secondly, we used a non-kinase inhibitor control compound since it would be 
informative as to the ability of the assay to identify both kinase inhibitors as well as non-
kinase inhibitor compounds which affect other types of cellular organelles such as 
mitochondria or ER. For example, decoupling of protein folding leads to activation of the 
unfolded protein response and cell death in cancers that are highly secretory such as 
Multiple Myeloma.9 Critical pathways and targets which regulate the unfolded protein 
response can be overlooked in a pure kinase screen.
A dose-response assay was done using EN460 ranging from 1–20 μM. Lethal effects were 
identified at the 10 μM dose, with 5 μM mostly viable through development and successful 
hatching of the embryos as can be seen in Figure 1. Subsequent assay development 
suggested the level of solvent DMSO was tolerated up to 5%, and the Z-factor for this assay 
was >0.9.10 Our data indicate that ERO1L dependent disulfide bridge formation is critical 
for proper development of zebrafish suggesting that the zebrafish HCS is a tractable strategy 
for screening modulators of the ER stress pathway.
Utilizing this assay format, we identified a novel compound from a HCS, compound 1 
(7745532) (Figure 2). Zebrafish embryos treated with compound 1 were found to be affected 
when treated from 6–30 hpf at varying concentrations. The embryos showed increasing 
morphological changes specifically in the notochord and the tail musculature resulting in a 
downward c-bend of the body axis. These phenotypical changes were not observable when 
the eggs were treated at 30 hpf, suggesting the target proteins are active in the first day of 
development and a low risk of overt toxicity in differentiated tissue. To narrow down the 
developmental window of time in which compound 1 had the greatest effect, we treated 
embryos starting at different developmental time points from 6 hpf to 26 hpf. We chose the 
100 μM dosage as it showed only a moderate effect on embryonic development from which 
we could determine changes in phenotypic severity. We saw visible changes to notochord 
and somite development with treatments from compound 1 at 6 to 14 hpf, however, beyond 
22 hpf, no gross morphological phenotype was observed. In addition the tail defects became 
localized more and more caudally with increasing developmental time suggesting that the 
targeted kinase is active in newly forming tail musculature or in a rostral to caudal gradient 
during development.
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To identify possible targets with which compound 1 interacts with, we tested compound 1 in 
a kinase panel (www.reactionbiology.com) since these small molecule inhibitors of kinases 
are attractive leads for cancer drug discovery.11, 12 The panel consisted of 369 wild type 
kinases which are commonly found to be drug targets in several disease types. Figure 3 
shows the results of the panel screen. The two kinases which were chosen from this screen 
for further exploration were PIM3 and DAPK1 as the two most extreme activities.
Compound 1 was found to inhibit PIM3 kinase with selectivity against PIM1 and PIM2. 
PIM kinases belong to the Ser/Thr kinase family and have been identified as novel oncology 
drug targets.13 Follow-up with a dose-response study found that compound 1 inhibited PIM3 
with an IC50 of 4.078 μM (figure 4). The control compound for the PIM3 kinase assay was 
staurosprine, with an inhibition of 0.1206 nM. Additionally, the kinase panel screen showed 
that compound 1 activated death associated protein kinase 1 (DAPK1). DAPK1 is a Ca2+/
calmodulin (CaM)-dependent serine/threonine protein kinase which plays a role in 
autophagy and apotptosis.14 This was a surprising finding in that compound 1 stimulated/
activated DAPK1 in contrast to the inhibition which we would have expected. A dose-
response assay indicated that compound 1 is able to stimulate the kinase activity with an 
EC50 value of 39.525 μM. The control compound for the DAPK1 kinase assay was 
staurosprine, with an inhibition of 9.4 nM (Figure 4).
To evaluate the interaction between compound 1 and the two kinases identified from the 
panel screen, docking studies were done. Since the crystal structure of PIM3 has not been 
published we developed a homology model of the PIM3 kinase, based on the PIM1 crystal 
structure using PIM1 (2BZN) as template (Figure 5).15 We utilized the homology modeling 
builder function in the program YASARA (www.yasara.com). For the docking study, the 
PIM3 homology model was prepared for docking in MOE 2016.08 (www.chemcomp.com) 
by adjusting the hydrogens and charge states of the amino acids to a pH of 7.4. Induced fit 
docking was used to evaluate the interaction of compound 1 with PIM3 kinase. Figure 4 
shows the top docked pose in the ATP binding pocket of PIM3. The main amino acids 
interacting with compound 1 is ARG125 and VAL54 (Figure 6A and B).
We also evaluated the interaction between compound 1 and DAPK1 (5AUT.pdb)16 using 
molecular modeling docking studies (Figure 6C and D). Since compound 1 activates/
stimulates DAPK1, we posited that ATP would be in the ATP binding pocket and 
allosterically modulate it.17 Using MOE 2016 we docked ATP into the binding site of 
DAPK1 kinase similar to our previously published methods18. Using this model as our 
starting point, compound 1 was docked into the ATP binding pocket area with the 
OEDOCKING 3.2.0.3/FRED program as part of the OpenEye drug discovery suit 
(www.eyesopen.com). An advantage of using OEDOCKING/FRED19 is that a spatial box is 
delineated in which the compounds are docked. By extending the box around the ATP 
binding pocket of DAPK1 kinase which had the ATP bound to the model, we were able to 
find a docking solution that fits the hypothesis that compound 1 is able to allow for the ATP/
kinase transition activity to occur in a more favorable state as compared to the kinase 
alone.18 As can be seen from this study, compound 1 is able to allow for an optimized 
positioning of the ATP for the gamma phosphate transfer to occur. This docking pose in part 
may explain the kinase activation by compound 1.
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In contrast compound 1 did not inhibit or stimulate DAPK2. From our docking studies we 
found that compound 1 only weakly interacts with DAPK2 kinase (2YAA.PDB) via a 
hydrogen bond to the carboxylic acid group, and is lacking the interactions of the adenosine 
moiety to GLU94 and VAL96 as can be seen with ATP (Figure 7).20 Additionally, there is a 
water network seen interacting with the phosphates of ATP (Figure 7). We posit that 
compound 1 is unable to bind to the pocket of ATP or orient itself to promote a stronger 
interaction for ATP with the kinase due to the waters in contrast to DAPK1. To our 
knowledge this is the first example of a small molecule which augments DAPK1 kinase 
activity.
Since several brain cancers such as from metastatic breast cancer are difficult to treat due to 
low brain distribution of the drug,21 we evaluated the permeability of compound 1 across an 
artificial barrier. The parallel artificial membrane permeability assay (PAMPA) is used in 
HTS screening which correlates to the permeability across the blood-brain barrier (BBB).22 
In this 96 well micotiter plate assay compound 1 was added at 200 μM to the donor 
compartment containing phosphate buffered saline (PBS pH 7. 4)/5% v/v DMSO and 
allowed to distribute across the hexadecane in hexane (5% v/v) organic layer on a filter plate 
to the acceptor compartment for 5 hours. The logPe was −3.735 suggesting that compound 1 
may be able to move across the BBB. The efflux proteins such as p-glycoprotein (PGP) 
which part of the ABC cassette transporters play an important role in both brain distribution 
of a chemotherapeutic drugs as well as the accumulation of cancer drugs into tumor cells. 
We evaluated compound 1 for affinity for the PGP efflux transports in MDB-MB-231 breast 
cancer cells (Figure 8). This HTS assay follows the accumulation of the fluorescent 
Rhodamine 123 into the cells after the pre-treatment with the compounds for 2 hours. 
Fluorescence in the 96 well plates is determined with a BioTek Synergy 4 plate reader 
(Ex/Em 485/528). Figure 6 shows that compound 1, tested at 50 μM, does not affect the 
accumulation of Rhodamine 123 suggesting that compound 1 does not act as substrate for 
the PGP transporter. The voltage gated calcium channel blocker (VGCC) verapamil was 
used as positive control at 20 μM. These data suggest that compound 1 would not be actively 
transported from the cancer cells, and in the case of the BBB permeability would not be 
effluxed by PGP.
Phenotypical high content screens have the advantage of identifying compounds with drug-
like pharmacokinetic properties (Distribution, metabolism and pharmacokinetics studies; 
DMPK) due to the involvement of organisms. In the case of the identified compound 1, we 
evaluated the serum albumin (SA) binding with the use of a bovine serum albumin (BSA) 
HTS screen. This HTS assay measures the quenching of the tryptophan in the BSA structure 
with Ex/Em 280/340 nm. As can be seen from figure 8 compound 1 has some affinity for 
serum albumin, with an IC50 of 23.29 μM. This suggests that compound 1 will be able to 
have sufficient free fraction in the serum for pharmacodynamic interaction with the PIM3 
kinase.
In conclusion, here we show the use of zebrafish embryos to identify a novel compound 
which can serve as lead for drug discovery campaigns. Compound 1 was able to inhibit 
PIM3 selectively and was found to activate DAPK1 kinase, which could prove to be a useful 
tool in drug discovery. This compound can be used as lead to develop novel anticancer 
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drugs. Future studies will be directed at increasing the selectivity of this lead compound for 
specificity towards Pim3 kinase inhibition or DAPK1 activation. Additionally, as neither 
kinase has been characterized in vertebrates, we also plan to develop better tools for 
dissecting the role of each of these kinases on the observed notochord and muscle 
deformation defect in zebrafish embryos.
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Screening of the ERO1 inhibitor in zebrafish embryos. As can be seen, EN460 significantly 
affected the tail and notochord leading to an observable phenotypic change. At increasing 
concentrations of drug the morphological defects of the developing embryos became more 
and more severe. Defects were categorized according to degree of tail shortening and 
curvature (Mild to Severe) to effects on the entire embryo from head to tail (Extreme), A – 
E. Counts were normalized by treatment group to percentages of those embryos affected out 
of the total number treated. Treatment with 10 – 20 μM dosages resulted largely in death of 
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the embryos, F. The number of embryos treated with each dosage are: 0 μM control = 108, 1 
μM = 48, 5 μM = 108, 10 μM = 108, 15 μM = 108, 20 μM = 48.
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High content screen identified compound 1. Zebrafish embryos were treated from 6–30 hpf 
in 12-well plates, n = ~30 embryos/group (A–C). Each well contained 1 mL of E3 media 
plus 1% DMSO with or without compound 1. At increasing concentrations of compound 1 
the morphological defects of the developing embryos became more and more severe and 
were categorized based on severity of tail curvature with accompanying defects in somite 
and notochord development (Moderate and Severe). Death was hardly observed at even the 
highest compound 1 dosage of 200 uM (D). To determine the developmental window of time 
in which compound 1 causes these morphological defects we treated embryos with the 100 
uM dose starting at different developmental time points until they were scored at 30 hpf (F). 
Using this methodology we determined that compound 1 targets a kinase between 6–14 
hours of development when the notochord and somites are first forming as no defects were 
observed from treatment at this moderate dose after 14 hpf. We also observed that at the later 
treatment time of 14 hpf notochord and somite defects were localized more caudally 
compared to the earlier treatment time of 6 hpf (white arrows, B treatment starting at 6 hpf 
verses E treatment starting at 14 hpf). This suggests that the targeted kinase is active in 
different regions of the developing tail at distinct developmental time points, largely in 
newly forming body segments. G and H show examples of embryos treated from 30–48 hpf 
with 1% DMSO (control) or 1% DMSO plus compound 1 (treatment). At all dosages tried, 
embryos looked morphologically normal at this later treatment time.
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Kinase panel screen of 369 typical kinases with ATP as substrate. Compound 1 was tested at 
10 μM. The two kinases which were chosen from this screen were the PIM3 and DAPK1 as 
the two most extreme activities. N = 2.
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Compound 1 was found to inhibit PIM3 selectively, compared with PIM1 and PIM2 (A) and 
activate DAPK1 kinase, in contrast to DAPK2 and DAPK3 (C). Staurosporine was used as 
positive control for PIM3 (B) and DAPK1 (D). N = 2.
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Structural alignment of the protein sequences of PIM3 and PIM1 for homology modeling 
(ClustalW alignment; A). The homology model of PIM3 was generated using YASARA 
software with PIM1 (2BZH) as structural template.
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Compound 1 which was identified from the HCS in zebrafish embryos docked into the 
homology model of PIM3 (A) and the amino acid interactions (B). DAPK1 kinase activation 
is thought to occur via optimal orientation of the ATP for phosphorylation (C (Pymol) and D 
(VIDA)).
Geldenhuys et al. Page 16














Compound 1 interaction with the ATP binding pocket of DAPK2 (PDB: 2YAA). Compound 
1 does not bind to DAPK2 via GLU94 and VAL96 as is seen with ATP (A and B), as well as 
the presence of a water bridge (C) prevents compound 1 from affecting the ATP phosphates 
(D and E) possibility as was suggested with the DAPK1 docking study.
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Compound 1 was evaluated in vitro for serum albumin binding (A) as well as affinity for the 
efflux transporter P-glycoprotein. *P<0.05.
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